EC1
stringlengths 22
351
| CT_title
stringlengths 38
384
|
|---|---|
[exclusion] cardiac ventricular arrhythmias requiring anti-arrhythmic therapy | A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer |
[exclusion] diagnosed Inflammatory Bowel Disease (IBD) | A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy |
[exclusion] patients treated for a prior invasive breast malignancy are excluded. Contralateral DCIS ≥ 10 years prior to enrollment is permissible | A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO) |
[exclusion] receive an irritation score of 1 (any redness, swelling, rash, or dryness present at any treatment area) for any individual skin condition prior to the Treatment Day baseline sample collection | Preoperative Skin Preparation Study Following ASTM E1173 Methods to Evaluate the Antimicrobial Capabilities of Four Test Substances |
[exclusion] requires prophylactic antibiotics for chronic infections, or has required 2 or more courses of antibiotics for infections in the 2 months prior to signing consent | Muscle Cell Mediated Therapy for Tongue Dysphagia: An Investigation of Cook MyoSite Autologous Muscle Derived Cells |
[exclusion] history of seizures | Immunogenicity Study of the Antibody Persistence and Booster Effect of the DTaP-IPV-Hep B-PRP~T Combined Vaccine at 15 to 18 Months of Age Following a Primary Series of DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™ Administered at 2, 4, and 6 Months of Age in Healthy Mexican Infants |
[exclusion] patients who have long-term tracheostomy | Randomised, Multicentre, Double-blind, Placebo-controlled Study to Assess the Safety, Efficacy and Pharmacodynamics After the Intravenous Administration of CAL02 in Severe Community-acquired Pneumonia Due to Streptococcus Pneumoniae |
[inclusion] participants must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below: Platelet count >= 100 x 10^9 /L | Nivolumab as a Non-Castrating Therapy for MMR-deficient and CDK12- Altered Prostate Cancer With PSA Recurrence After Local Therapy |
[inclusion] subjects must have undergone a prior ASCT for multiple myeloma and have progressed within 365 days of stem cell infusion. Progression is defined according to IMWG criteria49 | Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma |
[exclusion] sudden hearing loss with certain causes, | The Effect of Positive Airway Pressure on Idiopathic Sudden Sensorineural Hearing Loss Comorbided With Obstructive Sleep Apnea: A Clinical Randomized Controlled Study |
[inclusion] at least single haplotype matched (≥ 3 of 6) family member | TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies |
[inclusion] albumin ≥ 3.0 g/dL | Clinical Trial of Sir-Spheres® in Patients With Symptomatic or Progressive Hepatic Metastases From Neuroendocrine Tumors |
[inclusion] absolute neutrophil count 1500/mm3 | CeCil: A Randomized, Non-comparative Clinical Trial of the Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma |
[exclusion] evidence upon examination of any diabetic retinopathy, defined as eyes of diabetic patients with more than one microaneurysm outside the area of the vein occlusion (inclusive of both eyes) | A Multicenter Randomized Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion |
[exclusion] atrial fibrillation, if a frequency > 100/min or a large frequency variation, according to clinical judgment | Growth Hormone Treatment in Patients With Ischemic Heart Failure and Circulating Levels of NT-proBNP |
[inclusion] platelets >= 100,000/mm^3 | A Phase I Study of Herceptin/Flavopiridol in HER-2 Positive Metastatic Breast Cancer |
[inclusion] patients must have at least one of the following: Patients with refractory or chemo-resistant multiple myeloma (MM), as defined by a failure to respond (<50% reduction in M-protein level), or disease progression less than 2 months after receiving at least two conventional chemotherapy regimens | A Phase I/II Multi-Dose Study of SGN-30 in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies |
[exclusion] history of acute myocardial infarction, acute coronary syndrome or coronary artery bypass graft (CABG) in 6 months | A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Colorectal Cancer as 3rd or Above Therapy |
[exclusion] received any vaccination within 28 days prior to leukapheresis or blood collection for Treg manufacture | Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Liver Transplantation (RTB-002) |
[exclusion] subjects deemed by the clinician to have a bacterial infection | Bacteremia From Dental Extractions vs. Oral Hygiene |
[inclusion] prior hormonal therapy for locally recurrent or metastatic disease allowed | Phase II Randomized Trial of Ixabepilone Administered Weekly or Every Three Weeks in Patients With HER-2 Negative Metastatic Breast Cancer Previously Treated With Chemotherapy in the Neo-adjuvant or Adjuvant Setting |
[exclusion] having one of the following surgeries or procedures during warfarin interruption: Neurosurgery that is intracranial or intraspinal, such as tumor resection or aneurysm repair | Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery |
[exclusion] previously untreated NHL | A Phase I/II Open-label Study of Clofarabine in Patients With Relapsed or Refractory Diffuse Large Cell B-Cell NHL |
[exclusion] serum triglyceride levels >= 1000 mg/dl | Double Blind Randomised Controlled Trial to Investigate the Efficacy of ANTOX (Vers) 1.2 and MGCT (Magnesiocard) for the Treatment of Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis |
[inclusion] pre-operative cranial magnetic resonance imaging (MRI) (recommended with gadolinium) or pre-operative computed tomography (CT) (recommended with contrast) | A Phase II Study for the Treatment of Non-metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age |
[exclusion] patients who have a history of malignant tumors in 5 years prior to the study with the exception of Carcinoma in situ. | Multi-center, Open, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of MG4101 in Hepatocellular Carcinoma After TACE |
[exclusion] any history of malignancy (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence) | A First in Human Double-blind, Randomized Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults |
[exclusion] prior history of heart failure | ARomatherapy for Cognitive Trajectory in Chinese After Percutaneous Coronary Intervention (ARCTIC-PCI): a Randomized, Double-blind, Placebo-controlled Trial |
[inclusion] platelets ≥ 100 x 109/L | A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer. |
[exclusion] atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, or other skin disease associated with itch | A Phase III, Multicenter, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Antihistamine Treatment (H1) |
[inclusion] anatomic imaging (CT or MRI) of all sites of disease along with chest CT at baseline and restaging for all patients will be done to allow for assessment of RECIST progression. RECIST progression will determine progressive disease regardless of other imaging | Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma |
[inclusion] positive Xpert TB/RIF (original or Ultra) for MTB | A Novel 4-month Pan-TB Regimen Targeting Both Host and Microbe (panTB-HM) |
[exclusion] have a history of thromboembolic disease or thrombotic tendency | Study on the Effect of Metformin vs Metformin Combined With GLP-1 RA (Exenatide) on Overweight/Obese Patients With Polycystic Ovary Syndrome (PCOS) |
[exclusion] history of IBD | A Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Prulifloxacin Versus Placebo in the Treatment of Acute Gastroenteritis in Adult Travelers |
[inclusion] ineligible for or refused allogeneic bone marrow transplantation | A Pilot Study Of FR901228, Or Depsipeptide (NSC #630176) For Adult Patients With Advanced Hematologic Cancers |
[exclusion] subject has a history of status epilepticus within a year of screening while complying with AEDs | A Double-blind, Randomised, Placebo-controlled Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Primary Generalised Tonic Clonic Seizures |
[inclusion] be postmenopausal as defined by the National Comprehensive Cancer Network as either: Age <55 years and one year or more of amenorrhea, with an estradiol assay <20 pg/mL | Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor |
[inclusion] progression of disease or relapse following treatment with nivolumab or pembrolizumab. Intervening treatments with between PD-1 mAb therapy and the trial are permitted | A Phase II Trial of Ipilimumab With and Without Nivolumab in Patients With Relapsed/Refractory Classic Hodgkin Lymphoma |
[inclusion] this is the first clinically-recognized episode of viral respiratory tract infection after transplant | Does Increasing Immunosuppression Prevent Transplant-associated Lung-disease Triggered by Viral Respiratory Tract Infection Following Allogeneic Stem Cell Transplant? A Pilot Study |
[inclusion] agree to use male condom when engaging in any activity that allows for passage of ejaculate to another person | An Open Label, Randomized, Balanced, Three Treatment, Three Period, Three Sequence, Single Dose, Crossover Study to Evaluate the Bioequivalence of Test Griseofulvin Tablets, 500 mg Versus Reference Griseofulvin Tablets, 500 mg as Well as Dose Proportionality of Test Griseofulvin Tablets, 250 mg and 500 mg, in Healthy, Adult Participants Under Fed Conditions |
[inclusion] primary lung transplant | Pilot Study of Cyclosporine A Dry Powder Inhalation in Lung Transplant Patients With Bronchiolitis Obliterans Syndrome |
[inclusion] no other malignancy requiring treatment that would preclude study treatment, including, but not limited to, any of the following: Acute leukemia | Primary Effusion Lymphoma: A Pilot Trial of Bevacizumab and Modified Dose-Adjusted Infusional CDE Chemotherapy Preceded by a Brief Pre-Phase Assessment of Targeted Oncolytic Virotherapy With Bortezomib, Zidovudine and Valganciclovir |
[exclusion] therapy naïve patients | Double-blind, Placebo-controlled, Randomized Phase II-study Investigating the Efficacy of Bevacizumab for Symptom Control in Patients With Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers |
[exclusion] subjects on the following medications, at doses above the specified limits, are excluded if they cannot maintain a level within these limits | A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis |
[inclusion] active disease, based on Screening clinical and laboratory criteria, despite taking methotrexate for at least 3 months | A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate Multiple Dose Levels of Duvelisib With Background Methotrexate in Subjects With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone |
[exclusion] severe malnutrition or dysgenopathy at the screening visit | A Phase III, Multiple-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of an Adjuvanted, Inactivated Enterovirus 71 (EV71) Vaccine in Healthy Infants and Children |
[exclusion] has undergone major surgery within 3 months of the scheduled hysterectomy | A Phase II, Randomized, Single-dose, Unblinded Study to Compare the Efficacy and Safety of the CollaRx Bupivacaine Implant With the ON-Q PainBuster Post-op Pain Relief System in Women Following Abdominal Hysterectomy |
[exclusion] patients with diverticulosis | A Pilot Study to Evaluate the Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis |
[inclusion] pure or mixed histology | A Phase II Single-Arm Trial to Evaluate Cisplatin and Gemcitabine Chemotherapy in Combination With Sunitinib for First-Line Treatment of Patients With Advanced Transitional Carcinoma of the Urothelium |
[exclusion] abscess with horseshoe formation | Aspiration or Surgical Drainage of Perianal Abscess. A Randomized Controlled Clinical Study |
[exclusion] prior chemotherapy, targeted small molecule therapy, or radical therapy within 2 weeks prior to Study Day 1 | Camrelizumab Plus PEG-rhG-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure |
[exclusion] presence of bradycardia or a history of seizures | A Prospective, Randomized, Double Blind Study Comparing the Efficacy and Safety of Fentanyl Nasal Spray to Placebo as an Analgesic, in Patients Undergoing Outpatient Cystoscopic Procedures |
[exclusion] phase 2A will be limited to enrolling the following tumor types: Gastric, Esophageal, and G-E Junction Adenocarcinoma | A Phase 1/2A Multicenter, Open-Label Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer |
[exclusion] blood donation: blood donations for 3 months before this study | Two-way Crossover, Randomised, Single Dose and Two-stage Bioequivalence Study of Carbocysteine-L-lysine Salt 1.35 g Powder for Oral Solution Formulation vs 90 mg/mL Syrup Formulation After Oral Administration to Healthy Volunteers. |
[exclusion] acute pain at time of testing | Analgesic Effect of Oxytocin Receptor Modulation in Healthy Volunteers |
[exclusion] known to be affected by porphyria | Pilot Study to Evaluate Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions (Clinical and Sub-clinical), When Treated With Aldara 5% (Imiquimod) Cream |
[inclusion] knee pain for at least three months, occurring in at least half of the days in that period | The Use of Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis. A Double-Blind, Randomized Control Study |
[inclusion] no significant peripheral neuropathy ≥ grade 2 | A Phase II Study of Paclitaxel Poliglumex (PPX) in Combination With Transdermal Estradiol for the Treatment of Androgen Independent Prostate Cancer After Docetaxel Chemotherapy |
[inclusion] hospitalized patients with positive covid-19 swab with respiratory symptoms and CT confirmation of covid-19 chest disease admitted to non ITU recovery area | Studio in Aperto Sulla Somministrazione di Plasma di Paziente Convalescente da COVID- 19 a Paziente Con Polmonite COVID-19 Ospedalizzato, Non in Terapia Intensiva |
[exclusion] prothrombin time/INR or aPTT (in the absence of Lupus anticoagulant) >2 x ULN | Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression |
[exclusion] subjects receiving systemic corticosteroid treatment within one month of Screening Visit | Preliminary Examination of the Effects of Sodium Pyruvate Nasal Spray (N115) on Symptoms Associated With COVID19 Long Haulers. |
[exclusion] patients with a recent history (< 1 year) of myocardial infarction and/or (< 3 years) of heart failure or patients with any cardiac arrhythmia requiring drug therapy | Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Lamotrigine Efficacy in Asthma Therapy |
[inclusion] subject has soft tissue deficiencies, soft tissue post traumatic malformations, scars, and/or abnormal wound healing | A Phase I Open-labeled, Single-arm, Single-centred Study to Test the Safety of ADSC-SVF-002 in Subjects With Soft Tissue Defects or Abnormal Wound Healing |
[exclusion] have congenital heart disease, valvular heart disease, and other identified cause of pulmonary hypertension (including pulmonary fibrosis) unrelated to SCD | An Exploratory Study of Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease |
[exclusion] uncontrolled hyper or hypothyroidism | Evaluation of Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir Plus Ribavirin Based Therapy for Chronic Hepatitis C With or Without Compensated Cirrhosis in Haemodialysis Patients |
[exclusion] the subject has, in the judgment of the Investigator, a history or current medical condition that could affect safety including, but not limited to: Symptomatic cardiomyopathy at Day 0 | An Open-Label, Multi-Center, Long-Term Extension Study to Evaluate the Safety and Tolerability of Orally Administrated Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy |
[exclusion] donated blood or plasma within 8 weeks before the first dose administration | A Two-Part, Phase 1 Study to Evaluate Pharmacokinetics and Pharmacodynamics of Multiple Dose CC-90001 and to Evaluate the Effects of Food and Formulation on Pharmacokinetics of Single Dose CC-90001 in Healthy Subjects |
[exclusion] history of any of the following clinically significant conditions: Asplenia or functional asplenia | Phase 1b Trial to Evaluate Safety, Tolerability and Immune Responses of 2 Monovalent Chimpanzee Adenoviral Vectored Filovirus (Ebola-S and Marburg) Vaccines to Healthy Adults, Collection of Plasma/Serum for the Purposes of Assay Development |
[exclusion] subjects with clinically symptomatic metastases to the central nervous system (CNS) or meninges, or other evidence of uncontrolled metastases to the CNS or meninges, judged by the Investigator. History CNS leukemia that is controlled with intrathecal therapy is allowed | An Open-label, Multi-center Phase Ib/II Study of CN201 in Adult Subjects With Precursor B-cell Acute Lymphoblastic Leukemia |
[exclusion] use of prescription medications known to affect platelet function | A Randomized, Double-Blind, Single-Center, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of Intravenous DTRI-031 in Healthy Volunteers |
[inclusion] prior cytotoxic regimen received in the neoadjuvant or adjuvant setting will count as a prior cytotoxic regimen if disease recurrence occurred during or within 6 months of completing the regimen | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) |
[inclusion] histologically confirmed GBM in first relapse | A Phase II, Multicenter, Open-Label Trial of the Safety and Efficacy of Tarceva (Erlotinib Hydrochloride) in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme) |
[exclusion] uterine factor infertility: Asherman's, submucosal fibroids, polyp greater than 1 cm at time of embryo transfer, uninterrupted hydrosalpinx | Comparison of Vaginal Progesterone Gel (Crinone 8%®) and Intramuscular Progesterone in Vitrified-Warmed Blastocyst Transfer Cycles |
[exclusion] pentoxifylline or cilostazol for relief of claudication symptoms | A Phase II Multicentre, Randomised, Double-Blind, Controlled, Parallel-Group Study to Evaluate the Walking Time Effect of Long-Term Ticagrelor in Comparison to Long-Term Aspirin Administration in Ambulatory Patients With Peripheral Artery Disease Undergoing Endovascular Revascularization - The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study TI-PAD I EVR |
[exclusion] a permanent pacemaker | A Proof of Principle Study of Ondansetron for the Prevention of Vasovagal Syncope: The Eleventh Prevention of Syncope Trial (POST11) |
[inclusion] men and women aged 18-70 with Type 2 diabetes as defined by: Or currently using insulin | Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM |
[inclusion] platelets ≥ 75,000mm3 (≥75 × 109/L) evaluated at least 7 days after platelet transfusion | A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation |
[inclusion] must have undergone a nephrectomy and/or metastasectomy ≥28 days prior to signing informed consent and ≤12 weeks prior to randomization | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) |
[inclusion] participant has prothrombin within normal values | Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter Pivotal Study Assessing the Efficacy and Safety of 15 mg Twice a Day (BID) of SER150 in Well-controlled Type 2 Diabetic Patients With Diabetic Kidney Disease and Macroalbuminuria in Treatment With an Angiotensin Converting Enzyme Inhibitor or an Angiotensin Receptor Antagonist |
[exclusion] has lost or donated >450 mL of whole blood or blood products within 30 days before screening | A Two-Stage, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of OP-101 (Dendrimer N-acetyl-cysteine) in Patients With Severe COVID-19 |
[inclusion] kidney Transplant recipients, after the first episode of cytomegalovirus infection, using the current immunosuppressive regimen: azathioprine or mycophenolate, tacrolimus and prednisone | Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence in Kidney Transplant Recipients (StopCMV: S=Sirolimus CMV= Cytomegalovirus) |
[exclusion] prior treatment of the head and neck region with radiation therapy | Non-Randomized Phase 2 Trial of Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma |
[exclusion] excluded at the investigator's clinical judgement of ADHD symptom severity | Effects of Oxytocin on Cognitive Control in Adults With Attention Deficit/Hyperactivity Disorder |
[exclusion] well controlled type-2 DM in treatment with only oral medications and diet | A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants With Multiple System Atrophy |
[exclusion] there is obvious cough blood within 2 months before entering the study, or the daily cough blood volume reaches half a teaspoon (2.5 ml) or more | Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer With Extrahepatic Metastasis |
[inclusion] PNH associated with either life-threatening thrombosis, cytopenia, transfusion dependence or recurrent and debilitating hemolytic crisis | Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients With Debilitating Hematologic Diseases |
[exclusion] post liver transplantation patients | ''To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure' |
[inclusion] patients scheduled to receive EGFR inhibitors (gefitinib, erlotinib, afatinib, cetuximab, etc.) as malignant tumors | The Preventive Effect of Topical EGF Cream for Dermatologic Adverse Events Related to EGFR Inhibitors |
[exclusion] the presence of any of the following will exclude a subject from enrollment: Prior allogeneic or autologous stem cell transplant | A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia Due to the IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions. |
[exclusion] subjects with a recent medical illness | Hypoglycemia Associated Autonomic Failure in Type 1 DM, SSRI and Exercise |
[inclusion] approved rescue medication for the treatment of nausea and vomiting is permitted at the discretion of the investigator. The rescue antiemetics allowed will include: ondansetron, granisetron and lorazepam | A Randomized Open Label Phase II Trial of Aprepitant (Emend) in Combination With Ondansetron Compared to Standard 5HT3 Serotonin Antagonist (Ondansetron) in the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Glioma Patients Receiving a Temozolomide Based Regimen |
[inclusion] prior radiation therapy will be allowed if there is active measurable disease burden | A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma |
[exclusion] subjects with a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the past 12 months | Clinical Study of Efficacy and Safety of Novel Targeted Drugs Combined With R-ICE Regimen in the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma |
[inclusion] participants are able to take low-dose aspirin at a dose of 75 -100 mg daily or have a documented contraindication to aspirin use | A Prospective, Randomized, Active (Warfarin) Controlled, Parallel-arm Clinical Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely and Effectively on Apixaban |
[inclusion] AML secondary to treatment or associated to myelodisplasia | Vinblastine Versus Oral Hydroxiurea in Newly Diagnosed AML With Hyperleukocytosis: a Phase 2 Clinical Study |
[exclusion] moderate or massive effusion of body cavity need treatment | An Open-label Phase I/II Clinical Trial of PT-112 Injection Alone in the Treatment of Patients With Advanced Solid Tumors and Advanced Hepatocellular Carcinoma |
[inclusion] one additional cytotoxic regimen for recurrent or persistent disease allowed | Phase I/II and Pharmacokinetic Study of Docetaxel Plus VEGF Trap (AVE0005, NSC# 724770) in Patients With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
[exclusion] patients included in other clinical trials in the previous month | Safety and Tolerability of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis: a Multicenter, Double-blind, Placebo Controlled Randomized Clinical Trial. |
[exclusion] related or unrelated cord blood units without full testing and negative results for hepatitis A, B, C, HIV, HTLV-1, CMV viruses | A Dose Finding Study of Total Body Irradiation for Conditioning Patients With Severe Aplastic Anemia Transplanted With Umbilical Cord Blood |
[exclusion] history of cerebral vascular accident or myocardial infarction within 3 months prior to Day 0 | A Phase III, Double-masked, Multicenter, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus |